Alfredo Perales‐Puchalt
0000-0003-4904-5050
Publication & Citation Trends
Publications
0 total
synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy
Cited by 0
Semantic Scholar
CTIM-33. PERSONALIZED MULTIVALENT DNA VACCINATION SAFELY INDUCES BROAD NEOANTIGEN-SPECIFIC T CELL RESPONSES IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN A CLINICALLY RELEVANT TIME SCALE
Cited by 0
Semantic Scholar
Abstract 1174: Incorporation of multisector analysis into the design of personalized DNA vaccines for patients with newly diagnosed glioblastoma
Cited by 1
Semantic Scholar
Abstract 1191: Personalized neoantigen DNA vaccine GNOS-PV02 and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma
Cited by 0
Semantic Scholar
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial OA
Cited by 167
Semantic Scholar
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape OA
Cited by 16
Semantic Scholar
Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
Cited by 38
Semantic Scholar
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.
Cited by 0
Semantic Scholar
Research Topics
Immunotherapy and Immune Responses
(48)
CAR-T cell therapy research
(35)
Cancer Immunotherapy and Biomarkers
(29)
Immune Cell Function and Interaction
(19)
Monoclonal and Polyclonal Antibodies Research
(13)
Affiliations
The Wistar Institute
ECRI Institute
Pennsylvania State University
Johnson & Johnson (United States)
Janssen (Belgium)